Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AWT020 |
Synonyms | |
Therapy Description |
AWT020 is a bifunctional fusion protein comprising a PDCD1 (PD-1) antibody and variant form of IL-2, which potentially increases antitumor immune activity and decreases tumor growth (J Immunother Cancer 2022;10 (Suppl 2):1104). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AWT020 | AWT-020|AWT 020 | PD-L1/PD-1 antibody 121 | AWT020 is a bifunctional fusion protein comprising a PDCD1 (PD-1) antibody and variant form of IL-2, which potentially increases antitumor immune activity and decreases tumor growth (J Immunother Cancer 2022;10 (Suppl 2):1104). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06092580 | Phase I | AWT020 | Phase 1 Study of AWT020 in Advanced Cancer | Recruiting | AUS | 0 |